Sharemaestro company-news research for Lisi S.A. (FII), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
PAR
France
Provisional evidence
Company news sentiment
FII news sentiment
Lisi S.A.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score50Neutral is 50
Early balanced news score
16/100 evidence confidence
100% direct company focus
2 current stories across 2 publishers
Current company news
Early balanced news score
2 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone50/100
→
Published 30-day score50/100
Latest source headline
Should Weakness in Lisi S.A.'s (EPA:FII) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
simplywall.st · 07 Aug 2026 21:43 · Source lookup
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
2 current stories are mapped specifically to FII.
What limits the score
Only 2 publishers currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.008.
Confidence is 16/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news2 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
15 Jul30 Jul13 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.008 after freshness weightingSource breadth40
2 independent publishersCompany relevance100
share tied directly to this companyFreshness33
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix12
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202658EUR 67.2+5.3%
31 Jul 202650EUR 63.8-4.6%
Provisional evidence
News subjects
What is shaping the score
Market update502 stories · 100%
Source mix
Where the evidence comes from
simplywall.st501 stories · 50%
webull.com501 stories · 50%
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
31 Jul50 neutral13 Aug 23:49
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Aug 23:49 | 58 | -2 | 39/100 (0) | 10 (+2) | Measured |
| 12 Aug 23:59 | 60 | +1 | 39/100 (+3) | 8 (+2) | Measured |
| 11 Aug 23:59 | 59 | +1 | 36/100 (-1) | 6 (+2) | Provisional |
| 07 Aug 23:59 | 58 | +8 | 37/100 (+12) | 4 (+3) | Provisional |
| 31 Jul 23:59 | 50 | Start | 25/100 | 1 | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#150Tone
simplywall.stDirect company coverageScored from headlineSource lookup
Should Weakness in Lisi S.A.'s (EPA:FII) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
- Published
- 07 Aug 2026 21:43
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- High · 93.6% · 6.1d old
- Duplicates
- 1 consolidated
#250Tone
webull.comDirect company coverageScored from headlineSource lookup
Calculating The Fair Value Of Lisi S.A. (EPA:FII)
- Published
- 31 Jul 2026 03:31
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 6.4% · 13.9d old
- Duplicates
- 1 consolidated
Earlier company news
FII news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Aug
13
2026
finance.yahoo.comArchivedPositive tone
CEZ AS (XPRA:CEZ) (Q2 2026) Earnings Call Highlights: Net Income Rises 10% as Windfall Tax ...
This article first appeared on GuruFocus. Revenue: Operating revenue decreased 5% year-on-year, primarily due to lower power prices. EBITDA: Down 20% to CZK59 billion, impacted by lower generation prices and reduced trading profits. Net Income: Increased 10% to CZK18.1 billion, driven by the absence of the windfall profit tax, which ended on December 31, 2025. Operating Cash Flow: Increased by CZK26 billion, or 55% year-on-year. Capital Expenditures (CapEx): Increased 30% year-on-year. Net Debt: Approximately 9% higher, approaching CZK200 billion. Generation and Mining EBITDA: Decreased by CZK14.5 billion, or 31%, due to lower power prices. Coal Generation EBITDA: Down 65% to CZK1.4 billion, despite similar production volumes. Distribution EBITDA: Increased by CZK2 billion, or 10%, with normalized electricity EBITDA up 15% and gas distribution normalized EBITDA up 25%. Sales Segment EBITDA: Decreased by CZK2.4 billion, partly due to lower margins in retail and wholesale. Income Tax: Fell to CZK5.5 billion from CZK23.1 billion, reflecting the removal of the windfall profit tax. Guidance (EBITDA): Raised to CZK109 billion to CZK114 billion from CZK107 billion to CZK112 billion. Guidance (Adjusted Net Income): Raised to CZK31 billion to CZK35 billion from CZK30 billion to CZK34 billion. Nuclear Generation: 15.3 terawatt-hours generated in the first half, with a full-year target of 30.6 terawatt-hours. Fossil Fuel Generation: Up 6% in the first half, with full-year coal generation expected to increase 9% and natural gas by 87%. Hedging: 76% hedged for 2027 at an average price of EUR88 per megawatt-hour. Warning! GuruFocus has detected 9 Warning Signs with XPRA:CEZ. Is XPRA:CEZ fairly valued? Test your thesis with our free DCF calculator. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Net income increased 10% year-on-year to CZK18.1 billion, driven by the end of the windfall tax. Operating cash flow rose 55% to CZK26 billion, providing strong liquidity. Distribution segment EBITDA grew 10%, with normalized electricity EBITDA up 15% and gas up 25%. Nuclear generation exceeded expectations, with 15.3 TWh produced in H1 and full-year guidance raised. Guidance for 2026 EBITDA and adjusted net income was raised by CZK2 billion and CZK1 billion, respectively. Negative Points EBITDA declined 20% to CZK59 billion, primarily due to lower power prices. Generation and mining segment EBITDA fell 31%, with coal EBITDA down 65%. Sales segment EBITDA decreased by CZK2.4 billion, impacted by lower margins and project delays. Trading profits were lower, with a negative revaluation of derivatives of CZK2.6 billion. Net debt increased 9% to nearly CZK200 billion, raising leverage concerns. Story Continues Q & A Highlights Q: Can you elaborate on the trading results, which were negatively impacted by derivative revaluations, and discuss the risk of windfall taxes being reintroduced given the current high power prices?A: Pavel Cyrani (Vice Chairman, Head of Sales and Strategy) explained that most of the trading effect is due to intra-year revaluation of energy contracts, which can swing between positive and negative (e.g., +CZK2.6 billion at the end of Q1 vs. -CZK2.6 billion now). He noted that 2026 is a slower year for base trading but expects a recovery to standard levels. Martin Novak (CFO) stated that windfall tax reintroduction is not on the table, as energy company profits are significantly lower than when the tax was introduced, and such a move would impair discussions about new projects and the CEZ Energy separation. Q: What is driving the positive performance in the Distribution segment, and how should we read across to 2027 regarding correction factors?A: Pavel Cyrani (Vice Chairman, Head of Sales and Strategy) attributed the outperformance to higher-than-expected consumption due to a colder winter and underlying recovery in industrial and hous
EARNINGSESGGUIDANCEHEDGINGNET INCOMEPOWER-GENERATION
- Published
- 13 Aug 2026 02:10
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
13
2026
finance.yahoo.comArchivedPositive tone
GFT Technologies SE (WBO:GFT) (H1 2026) Earnings Call Highlights: AI-Driven Growth and ...
This article first appeared on GuruFocus. Revenue: EUR462.6 million in H1 2026, a 5% increase in both euros and constant currencies. Adjusted EBIT: EUR33 million, up 8% year-over-year, with a margin of 7.1% compared to 6.8% in H1 2025. EBT: EUR24 million, up 26% year-over-year, with the EBT margin improving from 4.3% to 5.2%. Q2 Revenue: EUR233.04 million, a 6% increase versus Q2 2025. Q2 Adjusted EBIT: EUR16.5 million, a 10% increase versus Q2 2025. Order Backlog: Up 18% versus last year. Wynxx Soft Engineering Revenue: EUR24.4 million in actual influenced revenue in H1 2026. Wynxx Business Process Revenue: EUR14.8 million in actual influenced revenue in H1 2026. Wynxx Total Influenced Contract Value: Over EUR144 million since inception, representing 38% growth quarter-over-quarter. Operating Cash Flow: Minus EUR1 million, an improvement from minus EUR9 million in the prior year. Free Cash Flow (Adjusted): Improved to minus EUR8.3 million from minus EUR17.3 million a year ago. Employees: 11,805 at the end of June, flat versus the beginning of the year and up 3% versus June last year. Utilization Rate: Increased to 92.8%. Attrition: Reduced to 10.4%. Warning! GuruFocus has detected 7 Warning Sign with WBO:GFT. Is WBO:GFT fairly valued? Test your thesis with our free DCF calculator. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points GFT Technologies SE (WBO:GFT) reported solid revenue growth of 5% in H1 2026, with strong performance in key markets like Brazil (38%), Colombia (27%), Switzerland (22%), and Spain (13%). Profitability improved significantly, with adjusted EBIT up 8% to EUR33 million and EBT up 26% to EUR24 million, reflecting better earnings quality and disciplined execution. The Wynxx Agentic AI platform is scaling rapidly, with 113 clients, 12 countries, and total influence contract value reaching EUR144 million, up 38% quarter-over-quarter. The company won six next-generation core banking programs and a major AML platform go-live for a Tier 1 European bank, demonstrating strong domain expertise and client trust. The order backlog increased by 18%, driven by multi-year contracts, including SAP business in Brazil, providing strong visibility for future growth. Negative Points Revenue in Germany declined by 12% due to investment caution, and the UK business was down 18% in H1, though expected to return to growth in Q3. North America revenue declined 7% due to a low-margin pass-through business in Canada and unfavorable FX, with Canada down 12% in euro terms. Operating cash flow was negative at EUR1 million in H1, reflecting seasonality and working capital tied up in contract assets, though improved from last year. The company faces headwinds from FX in North America, which could impact revenue, though offset by tailwinds in Latin America. Internal AI token costs are rising, with an expected spend of around EUR1 million this year, requiring careful management and pricing adjustments. Story Continues Q & A Highlights Q: Can you provide a bridge for the adjusted EBIT guidance, specifically what to expect for M&A and capacity adjustments in H2, and what needs to happen to reach the 7.6% full-year margin from the 7.1% seen in H1? A: Jochen Ruetz (CFO): We expect FX-adjusted EBIT to be roughly flat in the second half. Capacity adjustments should be similar to H1, around EUR3.5 million. To reach the full-year margin, we will repeat the pattern of the last few years, with a stronger second half driven by more billable days, especially in South America. We expect a logical second-half margin of roughly 8% to achieve the overall guidance. Q: Where do you see the market cycle for bank-related IT services, and is sentiment improving? Also, did the six next-gen core banking projects significantly contribute to the strong order backlog growth? A: Marco Santos (CEO): We see improving sentiment among financial services clients, particul
AIEARNINGSFINANCIALSFXGUIDANCEREVENUE GROWTH
- Published
- 13 Aug 2026 02:05
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
finance.yahoo.comArchivedNegative tone
Changes to full-year guidance for BioMar
Aktieselskabet Schouw & Co. Today, BioMar has released an announcement with updated guidance for the full year 2026. BioMar now expects revenue in the range of DKK 17-18 billion against previously DKK 16-17 billion and EBIT in the range of DKK 1,200-1,300 million compared to previously DKK 1,100-1,200 million. BioMar constitutes a material part of the portfolio and is fully consolidated into the Schouw & Co. figures, and the information from BioMar will be incorporated into Schouw & Co.'s guidance. Schouw & Co. provides guidance to the market on revenue and EBITDA and will consider its consolidated full-year guidance based on the information from BioMar and the outlook for the other portfolio businesses no later than in connection with the release of the interim report scheduled on 14 August 2026. Aktieselskabet Schouw & Co. Jørgen Wisborg, Chairman of the Board of Directors Jens Bjerg Sørensen, President & CEO Please direct any questions to President Jens Bjerg Sørensen, telephone no. +45 86 11 22 22. Attachment 2026-08-12 FBM26-45 BioMar guidance ENG View Comments
GUIDANCE
- Published
- 12 Aug 2026 12:33
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
12
2026
finance.yahoo.comArchivedPositive tone
technotrans SE (WBO:TTR1) (Q2 2026) Earnings Call Highlights: Margin Resilience and Strategic ...
This article first appeared on GuruFocus. Revenue: EUR113.3 million in H1 2026, down 6% from EUR120.6 million in the prior year. EBIT: EUR8.0 million in H1 2026, compared to EUR8.4 million one year ago. EBIT Margin: Increased to 7.1% from 7.0% in the prior year. Gross Profit: EUR34.2 million, with gross margin improving to 30.2% from 29.8%. EBITDA: EUR11.2 million, compared to EUR11.9 million in the previous year; EBITDA margin rose to 9.9% from 9.8%. Net Profit: EUR4.9 million, down from EUR5.2 million in the prior year. Earnings Per Share: EUR0.71, compared to EUR0.75 in the previous year. Free Cash Flow: EUR0.5 million in H1 2026, down from EUR1.1 million in the prior year; positive at EUR0.9 million in Q2. Order Backlog: EUR96 million at the end of June, up 14% from the end of March. Book-to-Bill Ratio: 1.2, with order intake exceeding revenue by 20%. Technology Segment Revenue: EUR84 million, down from EUR90.8 million; segment EBIT margin improved to 4.4% from 4.3%. Services Segment Revenue: EUR29.4 million, close to the prior year's EUR29.8 million; EBIT margin remained high at 14.7%. Energy Management and Laser Revenue: Approximately EUR32 million, up 8% year-over-year; excluding laser, growth was 17%. Healthcare and Analytics Revenue: Approximately EUR17 million, up 6% year-over-year. Print Revenue: EUR36 million, down approximately 10% year-over-year. Plastics Revenue: Approximately EUR26 million, down 19% year-over-year. Equity Ratio: Solid at 63.6%. Net Debt: EUR14.5 million, up from EUR8.3 million at the end of 2025; net debt to EBITDA ratio at 0.62. Warning! GuruFocus has detected 7 Warning Signs with JSEJF. Is WBO:TTR1 fairly valued? Test your thesis with our free DCF calculator. Release Date: August 04, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points EBIT margin improved to 7.1% despite a 6% revenue decline, marking the seventh consecutive quarter of stable margins around 7%. Order backlog surged 14% to EUR96 million, with a book-to-bill ratio of 1.2, indicating strong future revenue visibility. Energy Management division grew 17% (excluding laser), driven by robust demand in data center liquid cooling and battery thermal management. Secured a major long-term plastics order with recurring revenue of over EUR10 million annually, plus several large cooling plant orders. Healthcare & Analytics revenue rose 6%, supported by a new liquid cooling system for CT scanners with orders exceeding expectations in Asia. Story Continues Negative Points Group revenue fell 6% to EUR113.3 million, primarily due to continued weakness in Print and Plastics markets. Plastics division suffered a 19% revenue decline, reflecting weak economic conditions and prolonged market downturn. Supply chain restrictions for heat exchangers, pumps, and compressors pose a risk to production and could impact second-half performance. Free cash flow turned positive only in Q2, with first-half cash flow at EUR0.5 million, impacted by working capital buildup. Management expects full-year revenue to likely land in the lower half of the EUR240-260 million guidance range due to ongoing market volatility. Q & A Highlights Q: Given the strong order intake, is it fair to assume the 2027 growth rate will exceed the H2 2026 growth rate?A: Michael Finger (CEO): Yes. The strategic wins, including the significant jump in plastics revenue which will be fully in place next year, will make a difference. Assuming market conditions stay stable and other markets perform as they have this year, we see a nice growth rate in 2027. Q: Can you shed light on which of the larger orders are reflected in the Q2 order backlog and which come on top? Will Q3 also see a positive book-to-bill ratio?A: Michael Finger (CEO): The EUR96 million order backlog reflects only the first half. The major plastics order announced last week is not included and comes on top. Regarding Q3, one month is done and we see a posit
EARNINGSGROWTH RATEGUIDANCEPLASTICSREVENUESUPPLY-CHAIN
- Published
- 12 Aug 2026 02:02
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
finance.yahoo.comArchivedPositive tone
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
The going has been strong for Regeneron Pharmaceuticals REGN over the past month. Shares of this biotech giant have surged 21.9% over the said time frame, outpacing the industry's growth of 4%. The stock has also outperformed the sector and the S&P 500 Index during this time. REGN's robust rally has been driven by better-than-expected quarterly results, which can be attributed to robust demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales. REGN Outperforms Industry, Sector and S&P 500 IndexZacks Investment Research Image Source: Zacks Investment Research Against this backdrop, a closer evaluation of the company's strengths and weaknesses can help assess its attractiveness as an investment opportunity. REGN's Eylea HD Gains Traction as Eylea Sales Decline While lead drug Eylea continues to face headwinds, Eylea HD is gaining traction, supported by steady label expansions. Eylea is an anti-VEGF therapy approved across multiple ophthalmology indications. Declining sales of this drug continue to pressure the company's overall revenues. Competitive pressure has intensified, particularly from Roche's RHHBY Vabysmo, which targets both angiopoietin-2 (Ang-2) and VEGF-A pathways and has gained meaningful traction in the retinal disease market. RHHBY's Vabysmo sales grew 8% to CHF 2 billion in the first half of 2026 on continued global growth. To combat the decline in Eylea sales, Regeneron introduced Eylea HD, a higher-dose formulation of Eylea designed to improve durability and extend dosing intervals, Eylea HD sales in the United States surged 52% year over year to $596 million in the second quarter of 2026, driven by strong uptake following recent FDA label expansions and growing physician confidence in its differentiated profile and flexible dosing regimen. In April 2026, the FDA approved the extension of dosing intervals for Eylea HD to up to every 20 weeks (5 months) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) following a year of successful response based on visual and anatomic outcomes. The regulatory body had earlier approved Eylea HD for the treatment of macular edema following retinal vein occlusion (RVO), with dosing of up to once every eight weeks after an initial monthly dosing phase. The FDA also approved a monthly dosing option for certain patients who may benefit from resuming this dosing schedule across all currently approved indications, including wet age-related macular degeneration, DME, diabetic retinopathy and RVO. Story Continues Eylea and Eylea HD were co-developed with Bayer BAYRY. Regeneron records net product sales in the United States, while Bayer records sales outside the country. It expects a further decline in Eylea sales in the second half of 2026 due to ongoing conversion to Eylea HD and increasing competition as multiple biosimilar versions enter the U.S. market. Strong Dupixent Sales Fuel REGN Profits REGN's top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi records global net product sales of Dupixent. Dupixent continues to deliver strong growth across key indications, including atopic dermatitis, asthma, nasal polyps and eosinophilic esophagitis, while newer uses such as COPD, chronic spontaneous urticaria, bullous pemphigoid and allergic fungal rhinosinusitis are gaining traction. Ongoing label expansions for Dupixent remain a key contributor to revenue visibility and profitability. Regeneron Strengthens Its Oncology Portfolio Regeneron's oncology franchise is anchored by its PD-1 inhibitor Libtayo (cemiplimab-rwlc), which is approved for use in certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC). Libtayo sales continue to be robust, driven by strength across non-melanoma skin cancers and NSCL
BIOTECHCOMPETITIONEARNINGSFDA-APPROVALONCOLOGYQUARTERLY RESULTS
- Published
- 11 Aug 2026 15:30
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
11
2026
finance.yahoo.comArchivedPositive tone
Rational AG (RATIY) (Q2 2026) Earnings Call Highlights: Record EBIT Margin and Strategic ...
This article first appeared on GuruFocus. Revenue (H1 2026): EUR642 million, up 8% organically and 6% after FX adjustments. Revenue (Q2 2026): EUR324 million, up 4% year-over-year. EBIT (H1 2026): EUR170 million, up 11% year-over-year, with a margin of 26.5% (24.3% excluding tariff refunds). Gross Margin (H1 2026): Improved to 59.8%. Operating Expenses (H1 2026): Increased 5% year-over-year to EUR250 million. iCombi Revenue (H1 2026): EUR562 million, up 5%. iVario Revenue (H1 2026): EUR79 million, up 14%, with North America growing 24%. Germany Revenue (H1 2026): Up 9%. Europe (ex-Germany) Revenue (H1 2026): EUR285 million, up 9%. North America Revenue (H1 2026): EUR154 million, up 4% (10% before FX effects). Asia Revenue (H1 2026): Down 2%, with China down 25%. EBIT Guidance (FY 2026): Margin expected around the upper end of the 25% to 26% corridor. Warning! GuruFocus has detected 11 Warning Signs with BOM:533581. Is RATIY fairly valued? Test your thesis with our free DCF calculator. Release Date: August 06, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Rational AG (RATIY) delivered solid first-half 2026 results with organic revenue growth of 8% and 6% after FX adjustments, exceeding growth rates from 2025 and 2024. The company achieved a record EBIT margin of 26.5% in H1 2026, driven by strong operational performance and a one-time tariff refund of EUR14 million. The innovative iHexagon product is gaining strong customer traction, as evidenced by a compelling customer testimonial highlighting significant improvements in cooking speed, energy efficiency, and food waste reduction. The iVario product line showed robust growth of 14% in H1 2026, with particularly strong performance in North America (24% growth), underscoring its market penetration potential. Management confirmed the full-year outlook, expecting mid to high single-digit revenue growth and an EBIT margin at the upper end of the 25%-26% corridor, supported by a healthy order backlog and continued strong demand in key markets like Germany and North America. Negative Points Revenue growth in Q2 2026 slowed to 4% due to pull-forward effects in the US from pre-buying ahead of price increases, which dampened sequential momentum. Sales in China declined by 25% year-over-year, primarily due to Yum China's shift to local sourcing, creating a significant headwind in the Asia region. The company faces rising input costs, including higher prices for steel, chemicals, and electronic components, which are expected to pressure gross margins in the second half of 2026. Tariffs on US exports are expected to total EUR28-29 million for the full year, with a similar impact anticipated in 2027, potentially requiring future price increases to offset. Geopolitical tensions, particularly the Middle East conflict, have negatively impacted sales in the region, with a decline of around EUR2 million in H1 2026 and elevated costs. Story Continues Q & A Highlights Q: Could you provide an update on the market development in China, the acceptance of the iCombi One product there, customer feedback, and whether the product has already secured any major chain or key account contracts in that region? A: Peter Stadelmann (CEO): Consumer sentiment in China remains subdued and continues to weigh on our business performance. The main headwind is the decline in sales to Yum China as KFC China is increasingly shifting towards a local sourcing strategy. At the same time, our street business is positive. The iCombi One sales team has been set up, and we are gaining new dealers for all products every month. Customer interest in the iCombi One is high, and as previously announced, we have already secured a contract with a new key account for the iCombi One. Q: Looking at guidance for this year, could you provide an update on the outlook for the second half and the remainder of the year, including input cost developments, demand trends
EARNINGSEBIT-MARGINGROWTH RATEGUIDANCEREVENUE GROWTHREVENUE-GROWTH
- Published
- 11 Aug 2026 02:04
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
07
2026
finance.yahoo.comArchivedPositive tone
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
Cytokinetics, Incorporated CYTK reported a second-quarter 2026 loss of $1.50 per share, narrower than the Zacks Consensus Estimate of a loss of $1.63 per share. In the year-ago quarter, the company reported a loss of $1.12 per share. Loss widened year over year due to higher SG&A expenses tied to costs associated with the commercial launch of Myqorzo and lower revenues. Revenues amounted to $28.6 million, which went down from $66.8 million in the year-ago quarter but surpassed the Zacks Consensus Estimate of $20 million. Cytokinetics' shares have surged 28.1% year to date compared with the industry's 3.6% growth.Zacks Investment Research Image Source: Zacks Investment Research CYTK's Myqorzo Launch Gains Momentum In December 2025, the FDA approved Myqorzo (aficamten) for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Net product revenues from Myqorzo were $25.3 million in the second quarter. U.S. net product revenues totaled $23.0 million, while Europe contributed $2.30 million, reflecting initial distributor inventory purchases in Germany. Commercial adoption continued to broaden. More than 700 unique U.S. healthcare providers prescribed Myqorzo by June 30. More than 80% of dispensed prescriptions were paid, and management's internal analysis indicated Myqorzo exited the quarter with greater than 40% new-to-brand prescription share in the cardiac myosin inhibitor category. Cytokinetics launched Myqorzo in Germany in June, marking its first European commercial rollout. The drug also received marketing authorization across the United Kingdom, while NICE recommended it for use in England and Wales. CYTK's Revenue Mix Shifts From Milestones Beyond product sales, quarterly revenues included collaboration revenues of $3.29 million, up from $2.42 million in the year-ago quarter. No license and milestone revenues were recorded in the period. That absence caused the sharp year-over-year decline in total revenues. The second quarter of 2025 included $64.35 million in license and milestone revenues tied to the Bayer BAYRY collaboration for aficamten in Japan. Cytokinetics Sees Higher Commercial Spending Research and development expenses declined 11.2% year over year to $97.81 million. The decrease reflected higher clinical trial activity, supply-chain costs and medical affairs spending in the prior-year period, partly offset by higher personnel-related costs in 2026. Selling, general and administrative expenses rose 58.8% to $104.40 million. The increase reflected Myqorzo launch costs, the U.S. sales force and higher nonsales personnel-related expenses, including stock-based compensation. Story Continues CYTK Ends Q2 With a Stronger Cash Position Cash, cash equivalents and investments totaled approximately $1.7 billion as of June 30, 2026, compared with $1.1 billion at the end of the first quarter. The increase primarily reflected a May public offering that generated approximately $760.1 million in net proceeds. The additional liquidity provides Cytokinetics with the financial flexibility to support the commercialization of Myqorzo and continue investing across its specialty cardiology pipeline. CYTK Raises 2026 Expense Guidance Cytokinetics now expects combined 2026 GAAP R&D and SG&A expenses of $860-$890 million, up from its prior projection of $830-$870 million. The company also raised its stock-based compensation expense guidance to $130-$140 million from $120-$130 million. Excluding stock-based compensation, combined R&D and SG&A expenses are projected to be in the $720-$760 million band. Management tied the increase primarily to commercial-readiness investments following positive ACACIA-HCM results and preparations for a potential 2027 Myqorzo launch in non-obstructive hypertrophic cardiomyopathy (nHCM). CYTK's Updates on Aficamten On the clinical front, ACACIA-HCM met both primary endpoints in symptomatic nHCM, showing statistically significant improvements in KCCQ Clinical Summary Score and peak VO2 vers
BIOTECHCLINICAL-TRIALSEARNINGSFDA-APPROVALFOURTH QUARTERPHARMA
- Published
- 7 Aug 2026 19:22
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
Aug
07
2026
finance.yahoo.comArchivedPositive tone
Bittium Oyj (HLSE:BITTI) Earnings Reset The Valuation Debate
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. How Bittium Oyj's Latest Earnings Shape the Investment Picture Bittium Oyj (HLSE:BITTI) reported half year 2026 sales of €57.9 million and net income of €7.5 million, compared with €42.3 million and €1.5 million a year earlier, which sharpened investor focus on the stock. Those figures, together with basic earnings per share from continuing operations of €0.211 compared with €0.043 a year ago, provide fresh data to reassess how Bittium Oyj stock fits into a wider portfolio. See our latest analysis for Bittium Oyj. Bittium Oyj's latest half year report has been followed by sharp share price momentum, with a 1 day share price return of 35.64% and a 7 day return of 34.45%, while the 1 year total shareholder return of 233.38% and very large 3 year total shareholder return suggest that recent strength is building on an already strong longer term record. If Bittium Oyj's recent move has you rethinking where growth could come from next, it can help to compare it with other focused opportunities in the market such as 55 AI infrastructure stocks The latest jump in Bittium Oyj's share price sits right next to a clear uplift in recent earnings. The key issue now is whether the valuation mainly reflects these business results or a surge in enthusiasm. Most Popular Narrative: 7% Overvalued The most followed narrative currently puts Bittium Oyj's fair value at €35.75 versus the last close at €38.25, which frames the latest earnings jump in a tighter valuation range. The surge in defense and security order intake, alongside multiple pilot deliveries and ongoing negotiations (notably with Spain's Indra Group and BAE in the UK), positions Bittium to benefit from the global upswing in defense spending and modernization cycles, supporting potential above-trend revenue growth over the coming years. Read the complete narrative. Want to see what sits behind that defense heavy story? The narrative leans on ambitious revenue expansion, firm margins, and a rich future earnings multiple. Curious which assumptions carry the most weight in that €35.75 fair value call. The narrative uses a 7.52% discount rate and ties its fair value to firm expectations for earnings growth, profit margins and a higher future P/E multiple than the broader software industry, which gives you a detailed framework to compare against your own assumptions for Bittium Oyj. Story Continues Result: Fair Value of €35.75 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, there is still a risk that delayed or cancelled defense contracts and slower international expansion could leave Bittium Oyj short of the forecast earnings path. Find out about the key risks to this Bittium Oyj narrative. Next Steps If the mix of optimism and concern around Bittium Oyj feels finely balanced, now is a good time to check the underlying data yourself and decide how that fits your approach. To see both sides of the story in one place, review the 2 key rewards and 1 important warning sign Looking for more investment ideas beyond Bittium Oyj? Use Bittium Oyj as a starting point, then widen your search with stock ideas that match different goals, risk levels, and income needs using the Simply Wall Street Screener. Spot potential bargains before they hit the spotlight by checking companies flagged in the screener containing 549 high quality undiscovered gems. Build confidence in your capital base by focusing on companies featured in the solid balance sheet and fundamentals stocks screener (422 results). Strengthen your income stream by reviewing companies highlighted in the 440 dividend fortresses. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to
BALANCE SHEETDEFENSEEARNINGSEARNINGS GROWTHEARNINGS PER SHARENET INCOME
- Published
- 7 Aug 2026 19:10
- Catalyst
- Market update
- Coverage
- Direct company
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.